Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:

• Introduction (0:00)
• Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)
• Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)

CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics:

• Introduction (0:00)
• Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12)
• Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54)
• Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49)
• Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12)
• Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26)

CME information and select publications

Dr Thomas Hutson from the Sarah Cannon Research Institute in Abilene, Texas, Dr Eric A Singer from The Ohio State University Comprehensive Cancer Center in Columbus and Dr Ulka Vaishampayan from the University of Michigan Health Rogel Cancer Center in Ann Arbor discuss recent data surrounding the management of localized renal cell carcinoma and share their perspectives on the clinical application.

CME information and select publications